PSC code
DRUGS AND BIOLOGICALS
- PSC code
- 6505
- Latest action
- Aug 8, 2026
Fewer than the minimum comparable awards under this PSC code.
Largest awards under this code
| Award | Contractor | Agency | Place | First action | Current value |
|---|---|---|---|---|---|
| 36C24026K1008 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 MAY | MCKESSON CORPORATION | Department of Veterans Affairs | TX | May 1, 2026 | $1,398,025,092 |
| HHSO100201700019C BAVARIAN NORDIC MOD 21 | BAVARIAN NORDIC A/S | Department of Health and Human Services | — | May 11, 2026 | $1,264,240,981 |
| 36C24026K1009 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JUNE | MCKESSON CORPORATION | Department of Veterans Affairs | TX | Jun 1, 2026 | $1,191,973,258 |
| 36C24026K1007 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 APRIL | MCKESSON CORPORATION | Department of Veterans Affairs | TX | Apr 1, 2026 | $1,191,348,081 |
| 36C24026K1006 EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 MARCH | MCKESSON CORPORATION | Department of Veterans Affairs | TX | Mar 1, 2026 | $1,175,683,451 |
| 75A50119C00037 VACCINIA IMMUNE GLOBULIN INTRAVENOUS (VIG-IV) BUY AND ASSOCIATES SERVICES FOR UP TO 10 YEARS. | EMERGENT BIOSOLUTIONS CANADA INC | Department of Health and Human Services | — | Mar 23, 2026 | $422,315,784 |
| 75A50119C00075 EO14042 BOTULISM ANTITOXIN | EMERGENT BIOSOLUTIONS CANADA INC | Department of Health and Human Services | — | Mar 30, 2026 | $320,923,453 |
| W911QY13C0056 TERMINATION SETTLEMENT PROPOSAL DEADLINE FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | DYNPORT VACCINE COMPANY LLC | Department of Defense | MD | Mar 26, 2026 | $257,417,661 |
| HHSO100201700012C IGF::OT::IGF | MERCK SHARP & DOHME LLC | Department of Health and Human Services | NJ | Sep 28, 2017 | $236,307,634 |
| 75A50126C00001 STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | DC | May 5, 2026 | $223,798,184 |
| 75A50122C00061 PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | CA | Sep 27, 2022 | $220,594,031 |
| 75A50124C00057 ERVEBO PROCUREMENT | MERCK SHARP & DOHME LLC | Department of Health and Human Services | NJ | Sep 27, 2024 | $155,843,515 |
| 75A50324C00006 ADMINISTRATIVE OBJECT CLASS CODE DEOBLIGATION-ANTHIM (OBILTOXAXIMAB) | ELUSYS THERAPEUTICS INC | Department of Health and Human Services | NJ | Jun 1, 2026 | $124,523,123 |
| 75A50322F80030 THE PURPOSE OF THIS MODIFICATION IS TO DESCOPE AMOXICILLIN TRIHYDRATE 500 MG CLINS. | CHARTWELL RX LLC | Department of Health and Human Services | NY | Mar 24, 2026 | $99,047,470 |
| 75N90025C00008 ADDITIONAL FUNDING | DLA TROOP SUPPORT | Department of Health and Human Services | PA | Apr 2, 2026 | $93,536,123 |
| 75A50325F80036 PROCUREMENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS | GENENTECH USA, INC | Department of Health and Human Services | CA | Mar 17, 2026 | $74,970,000 |
| 75A50122C00080 THE PURPOSE OF THIS MODIFICATION IS TO REPORT INFORMATION VIA FPDS FOR CONTRACTS BEING ALIGNED WITH THE PRESIDENTIAL COST SAVINGS INITIATIVE. EOI: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING | VENATORX PHARMACEUTICALS INC | Department of Health and Human Services | PA | May 13, 2026 | $72,141,707 |
| 75A50124C00046 SUPPLEMENTAL FUNDING TO THE BASE PERIOD (CLIN 0001, CLIN 0002 & CLIN 0003); EXERCISE OPTION 1 (CLIN 0004); UPDATE TRAVEL BUDGET; UPDATE GO/NO-GO MILESTONES; UPDATE INDIRECT RATES; UPDATE COA THRESHOLD TO $350,000; INCORPORATE MANDATORY CLAUSES AS | CERUS CORPORATION | Department of Health and Human Services | CA | Jul 21, 2026 | $65,358,564 |
| 75N98026C00026 PHARMACEUTICALS AND RELATED SUPPLIES UNITED STATES DEPARTMENT OF DEFENSE:1133869 [26-003472] | DLA TROOP SUPPORT | Department of Health and Human Services | PA | Apr 9, 2026 | $65,000,000 |
| 75A50118C00013 THE PURPOSE OF THIS MODIFICATION IS TO DEOBLIGATE CANCELING YEAR FUNDS FROM REQUISITION OS252049 IN THE AMOUNT OF (-$1.16) FROM CLIN00002. | SELUX DIAGNOSTICS, INC. | Department of Health and Human Services | MA | May 13, 2026 | $62,626,467 |
| HHSO100201100037C ADVANCEMENT OF HEMAMAX TOWARDS BLA SUBMISSION FOR THE MITIGATION OF HSARS UNDER THE FDA ANIMAL RULE | NEUMEDICINES INC. | Department of Health and Human Services | CA | Sep 15, 2011 | $54,163,469 |
| 75A50325F80003 EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI TERMINATION FOR CONVENIENCE AGREEMENT AND CLOSEOUT MODIFICATION. | GENENTECH USA, INC | Department of Health and Human Services | CA | Mar 27, 2026 | $45,106,864 |
| SPE2DP26F4183 8512025830!ANTIDOTE TREATMENT | MERIDIAN MEDICAL TECHNOLOGIES, LLC | Department of Defense | MO | Apr 7, 2026 | $36,470,000 |
| 75A50325C00020 RAFA ATROPINE AUTO-INJECTORS (0.5 MG, 1 MG, AND 2 MG) | RAFA LABORATORIES LTD | Department of Health and Human Services | — | Sep 30, 2025 | $33,392,937 |
| 75A50326F80004 AMOXICILLIN TRIHYDRATE 500MG 60 CT AND 100 CT ORAL CAPSULES | USANTIBIOTICS LLC | Department of Health and Human Services | TN | May 27, 2026 | $29,998,678 |
Related records
Derived from awards these records share, ordered by how many.
Bought by
Performed in
- Pennsylvania108,753
- Illinois9,109
- Ohio3,051
- Texas1,277
- South Carolina860
- New York732
- New Jersey555
- Virginia410
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals cover awards where the government recorded this PSC code. Codes are taken as reported; awards are never reclassified into a different code.
- 1Awards are grouped by the PSC code the government recorded on the award, taken from USAspending.gov and last refreshed Aug 10, 2026. Miscoded awards stay miscoded here; we do not reassign codes.